Long-Acting Treatments for Hepatitis B

Clin Infect Dis. 2022 Nov 21;75(Suppl 4):S517-S524. doi: 10.1093/cid/ciac718.


There are an estimated 257 million persons living with chronic hepatitis B for whom there are multiple potential applications of long-acting antiviral compounds. Current efforts include both injection and implant approaches to formulating derivates of existing anti-HBV compounds such as tenofovir or entecavir. Substantial progress has already occurred especially as aligned with the development of long-acting tenofovir-based medications with dual activity against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Nonetheless, substantial challenges will need to be overcome before these agents are available.

Keywords: anti-viral; hepatitis B virus; long-acting.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / therapeutic use
  • Hepatitis B virus
  • Hepatitis B* / drug therapy
  • Hepatitis B, Chronic* / drug therapy
  • Humans
  • Tenofovir / therapeutic use


  • Tenofovir
  • Antiviral Agents